<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771667</url>
  </required_header>
  <id_info>
    <org_study_id>CR015238</org_study_id>
    <secondary_id>C0743T26</secondary_id>
    <nct_id>NCT00771667</nct_id>
  </id_info>
  <brief_title>A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy</brief_title>
  <official_title>A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A medical research study in adult patients who have moderate to severe Crohn's disease
      designed to determine whether or not treatment with an experimental drug called ustekinumab
      (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of
      Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Crohn's disease there is inflammation (changes in body tissue which normally happen during
      injury or infection) and or ulceration (open sores) in the intestines.This occurs because the
      immune system (the part of the body that fights off infection) has an abnormal and overactive
      response against the intestine and bowel tissues of the body. Crohn's disease is usually
      treated with medications that either directly decrease inflammation or decrease the general
      activity of the immune system to improve the diarrhea, abdominal pain, and other symptoms of
      Crohn's Disease. Ustekinumab antibodies (natural substances made by your immune system to
      stick to and help remove foreign materials in your body that cause diseases) have been
      created to stick to and block the activity of two of the immune substances thought to cause
      abnormal inflammation of Crohn's disease. Patients who are eligible and who have received
      Remicade, Humira, or Cimzia and failed or been intolerant to one of these drugs will be
      randomized to either active drug (ustekinumab) or placebo. All patients will be randomized
      (like flipping a coin) at week 0 to be in one of 4 groups. At week 0 the study drug will be
      given by IV administration and at weeks 8 and 16 by subcutaneous injection. There will be 11
      study visits in total and the study will continue until week 36. Blood and stool samples will
      be collected and studied, questionnaires to check on how you are doing in terms of your
      disease will be completed, an Electrocardiogram (EKG) obtained, safety evaluations conducted
      and diary cards distributed to be completed during the entire study. One of 4 groups: Grp
      1-placebo, Grp 2-active drug 1mg/kg IV, Grp 3-active drug 3mg/kg IV, Grp 4-active drug 6mg/kg
      IV. Based on the clinical response status at Week 6, patients from Grps 2, 3 and 4 will be
      re-randomized at week 8 to receive either placebo or 90 mg SC at both weeks 8 and 16 and
      patients from Grp 1 will receive placebo at Week 8 and Week 16 or a 270 mg SC injection at
      Week 8 and 90 mg SC at Week 16.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>As measured by the Crohn's Disease Activity Index (CDAI). CDAI scores range from 0 points (minimal disease activity) to over 600 points (severe disease activity). Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Remission at Week 6</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>As measured by a CDAI score of &lt; 150 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Remission at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>As measured by a CDAI score of &lt; 150 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Remission at Week 22 (Among Responders From Week 6)</measure>
    <time_frame>Baseline to Week 22</time_frame>
    <description>As measured by a CDAI score of &lt; 150 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response at Week 22 (Among Responders From Week 6)</measure>
    <time_frame>Baseline to Week 22</time_frame>
    <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo (IP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab 1mg/kg (IP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab 3 mg/kg (IP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab 6 mg/kg (IP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV - Responder - Placebo SC (MP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab IV - Responder - Placebo SC (MP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab IV - Nonresponder - Placebo SC (MP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (IP)</intervention_name>
    <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
    <arm_group_label>Placebo (IP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 1mg/kg (IP)</intervention_name>
    <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group</description>
    <arm_group_label>Ustekinumab 1mg/kg (IP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 3 mg/kg (IP)</intervention_name>
    <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
    <arm_group_label>Ustekinumab 3 mg/kg (IP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 6 mg/kg (IP)</intervention_name>
    <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
    <arm_group_label>Ustekinumab 6 mg/kg (IP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV - Responder - Placebo SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16</description>
    <arm_group_label>Placebo IV - Responder - Placebo SC (MP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16</description>
    <arm_group_label>Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab IV - Responder - Placebo SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16</description>
    <arm_group_label>Ustekinumab IV - Responder - Placebo SC (MP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
    <arm_group_label>Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab IV - Nonresponder - Placebo SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16</description>
    <arm_group_label>Ustekinumab IV - Nonresponder - Placebo SC (MP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)</intervention_name>
    <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
    <arm_group_label>Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration

          -  Must have received Remicade, adalimumab or Cimzia at a dose approved for the treatment
             of Crohn's disease

          -  Must have failed or been intolerant to Remicade, Humira or Cimzia for treatment of
             Crohn's disease

          -  Must be 18 years of age or older

          -  Must have active Crohn's disease according to the Crohn's Disease Activity Index (CDAI
             &gt; =220 and &lt; =450).

        Exclusion Criteria:

          -  Patients who have had any kind of bowel resection, diversions or placement of a stoma
             within 6 months

          -  Are pregnant, nursing or planning pregnancy (both men and women) while enrolled in the
             study or within 1 year after receiving study agent

          -  Patients who have received Remicade, Humira or Cimzia &lt; =8 weeks before the first
             administration of study drug

          -  Patients with certain complications of Crohn's disease that would make it hard to
             assess response to study drug

          -  Patients with a history of or ongoing chronic or recurrent infectious disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Egg Harbor</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ny</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setauket</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bankstown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz N/A</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens Cedex 1 80</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9 N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin N/A</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lÿneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markkleeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma De Mallorca N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottinghamshirecc</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <results_first_submitted>October 10, 2011</results_first_submitted>
  <results_first_submitted_qc>June 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <disposition_first_submitted>April 26, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2011</disposition_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Research</name_title>
    <organization>Janssen R&amp;D US</organization>
  </responsible_party>
  <keyword>Interleukin-12</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Research study</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>CNTO1275</keyword>
  <keyword>Interleukin-23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 1 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab 3 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
        </group>
        <group group_id="P4">
          <title>Ustekinumab 6 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
        </group>
        <group group_id="P5">
          <title>Placebo IV -&gt; Responder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="P6">
          <title>Placebo IV -&gt; Nonresponder -&gt; Ustekinumab 270/90 mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16</description>
        </group>
        <group group_id="P7">
          <title>Ustekinumab IV -&gt; Responder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="P8">
          <title>Ustekinumab IV -&gt; Responder -&gt; Ustekinumab 90mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
        </group>
        <group group_id="P9">
          <title>Ustekinumab IV -&gt; Nonresponder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="P10">
          <title>Ustekinumab IV -&gt; Nonresponder -&gt; Ustekinumab 90mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
                <participants group_id="P6" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
                <participants group_id="P7" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
                <participants group_id="P8" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
                <participants group_id="P9" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
                <participants group_id="P10" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Induction period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Maintenance period.</participants>
                <participants group_id="P2" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Maintenance period.</participants>
                <participants group_id="P3" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Maintenance period.</participants>
                <participants group_id="P4" count="0">&quot;0&quot; in column indicates this reporting group is not relevant to Maintenance period.</participants>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="85"/>
                <participants group_id="P7" count="73"/>
                <participants group_id="P8" count="72"/>
                <participants group_id="P9" count="110"/>
                <participants group_id="P10" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="63"/>
                <participants group_id="P8" count="67"/>
                <participants group_id="P9" count="88"/>
                <participants group_id="P10" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="22"/>
                <participants group_id="P10" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
        </group>
        <group group_id="B2">
          <title>Ustekinumab 1 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
        </group>
        <group group_id="B3">
          <title>Ustekinumab 3 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
        </group>
        <group group_id="B4">
          <title>Ustekinumab 6 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="132"/>
            <count group_id="B4" value="131"/>
            <count group_id="B5" value="526"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="13.05"/>
                    <measurement group_id="B2" value="38.8" spread="11.95"/>
                    <measurement group_id="B3" value="38.2" spread="12.63"/>
                    <measurement group_id="B4" value="39.4" spread="13.21"/>
                    <measurement group_id="B5" value="39" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response at Week 6</title>
        <description>As measured by the Crohn's Disease Activity Index (CDAI). CDAI scores range from 0 points (minimal disease activity) to over 600 points (severe disease activity). Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 1 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 3 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab 6 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response at Week 6</title>
          <description>As measured by the Crohn's Disease Activity Index (CDAI). CDAI scores range from 0 points (minimal disease activity) to over 600 points (severe disease activity). Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed to control the type I error rate at 0.05 level for the primary endpoint, beginning with the highest dose.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed to control the type I error rate at 0.05 level for the primary endpoint, beginning with the highest dose.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>A fixed sequence testing procedure was employed to control the type I error rate at 0.05 level for the primary endpoint, beginning with the highest dose.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Remission at Week 6</title>
        <description>As measured by a CDAI score of &lt; 150 points.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 1 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 3 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab 6 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Remission at Week 6</title>
          <description>As measured by a CDAI score of &lt; 150 points.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.682</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Response at Week 4</title>
        <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 1 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 3 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab 6 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response at Week 4</title>
          <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Response at Week 8</title>
        <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 1 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 3 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab 6 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response at Week 8</title>
          <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Remission at Week 8</title>
        <description>As measured by a CDAI score of &lt; 150 points.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 1 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 3 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab 6 mg/kg (IP)</title>
            <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Remission at Week 8</title>
          <description>As measured by a CDAI score of &lt; 150 points.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for anti-TNF status.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Remission at Week 22 (Among Responders From Week 6)</title>
        <description>As measured by a CDAI score of &lt; 150 points.</description>
        <time_frame>Baseline to Week 22</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>As a single subcutaneous dose at Weeks 8 and 16</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 mg SC</title>
            <description>As a single subcutaneous dose at Weeks 8 and 16</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Remission at Week 22 (Among Responders From Week 6)</title>
          <description>As measured by a CDAI score of &lt; 150 points.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Testing for Week-22 clinical remission was performed if the comparison of 6-mg/kg ustekinumab with placebo was positive for the primary endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test chi-square test, stratified by IV induction dose and clinical remission status at Week 6.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Response at Week 22 (Among Responders From Week 6)</title>
        <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
        <time_frame>Baseline to Week 22</time_frame>
        <population>All participants who were randomized, regardless of whether they received study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>As a single subcutaneous dose at Weeks 8 and 16</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 mg SC</title>
            <description>As a single subcutaneous dose at Weeks 8 and 16</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response at Week 22 (Among Responders From Week 6)</title>
          <description>As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of &lt; 150 was attained.</description>
          <population>All participants who were randomized, regardless of whether they received study agent.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The CMH test is controlling for induction dose and clinical remission status at Week 6.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Placebo IV group</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 1 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 1mg/kg IV group</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 3 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group</description>
        </group>
        <group group_id="E4">
          <title>Ustekinumab 6 mg/kg (IP)</title>
          <description>Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group</description>
        </group>
        <group group_id="E5">
          <title>Placebo IV -&gt; Responder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="E6">
          <title>Placebo IV -&gt; Nonresponder -&gt; Ustekinumab 270/90 mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab IV -&gt; Responder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="E8">
          <title>Ustekinumab IV -&gt; Responder -&gt; Ustekinumab 90mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Responder at week 6 -&gt; Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
        </group>
        <group group_id="E9">
          <title>Ustekinumab IV -&gt; Nonresponder -&gt; Placebo SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Placebo SC at Week 8 and Week 16</description>
        </group>
        <group group_id="E10">
          <title>Ustekinumab IV -&gt; Nonresponder -&gt; Ustekinumab 90mg SC (MP)</title>
          <description>Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 -&gt; Nonresponder at week 6 -&gt; Receiving Ustekinumab 90 mg SC at Week 8 and Week 16</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Rectal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness-like reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="64" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="52" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Janssen Research and Development, US</organization>
      <phone>610-651-6554</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

